Biochemical and Biophysical Research Communications
Volume 165, Issue 3, 30 December 1989, Pages 1375-1381
Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative
References (19)
- et al.
J. Virol. Methods
(1988) - et al.
J. Virol. Methods
(1987) - et al.
- et al.
New Engl. J. Med
(1987) - et al.
New Engl. J. Med
(1987) - et al.
Science
(1989) - et al.
J. Med. Chem
(1989) - et al.
Science
(1985) - et al.
Cancer
(1965)
There are more references available in the full text version of this article.
Cited by (320)
Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023
2023, European Journal of Medicinal ChemistryThe CARD8 inflammasome in HIV infection
2023, Advances in ImmunologyAdvance of structural modification of nucleosides scaffold
2021, European Journal of Medicinal ChemistryLife-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq
2021, Biochemical PharmacologyCitation Excerpt :In 1987, the discovery of 2́,3́-dideoxy-2́,3́-didehydrothymidine [17], later marketed as stavudine (d4T) for HIV treatment. In 1989 and 1990, the discovery of HEPT [18,19] and TIBO [20] derivatives that were subsequently recognized as the prototypes of non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as rilpivirine [21,22]. In 1993, the discovery of [(R)-9-(2-phosphonylmethoxypropyl)adenine] [23], which was later developed as tenofovir for HIV and HBV treatment.
Uracil derivatives as non-nucleoside inhibitors of viral infections
2021, Annual Reports in Medicinal Chemistry
- ∗
Present address, Department of Bacteriology, Fukushima Medical College, Fukushima 960-12, Japan.
Copyright © 1989 Published by Elsevier Inc.